Loading...
•
Mar 31, 2023
Alkermes Q1 2023 Earnings Report
Alkermes reported strong first-quarter financial results driven by proprietary product net sales and disciplined cost management.
Key Takeaways
Alkermes plc reported first-quarter 2023 financial results, with total revenues of $287.6 million. The company saw strong performance in its proprietary product portfolio, with a 25% increase in net sales year-over-year. Alkermes is reiterating its financial expectations for 2023 and is progressing with the planned separation of its oncology business.
First Quarter Revenues of $287.6 Million Reflect Strong Performance of Proprietary Product Portfolio.
GAAP Loss per Share of $0.25 and Basic and Diluted Non-GAAP Earnings per Share of $0.01.
Planned Separation of Oncology Business Expected to be Completed in Second Half of 2023.
Financial Expectations for 2023 Reiterated.
Alkermes
Alkermes
Alkermes Revenue by Segment
Revenue by Segment
VIVITROL Revenue
CapyFin.comARISTADA Revenue
CapyFin.comLYBALVI Revenue
CapyFin.com Forward Guidance
Alkermes reiterates its financial expectations for 2023, as set forth in its press release dated Feb. 16, 2023.
Revenue & Expenses
Visualization of income flow from segment revenue to net income